ROCKVILLE, MD, UNITED STATES, March 8, 2019 / American Gene Technologies (AGT) is pleased to see the release of information about a second individual cured of HIV in London–recently reported in the Wall Street Journal and New York Times. The patient was treated with a bone marrow transplant from a CCR5-Δ32 donor. The London Patient… [Read More]
American Gene Technologies (AGT) Granted Three New Patents in its HIV Cure and Immuno-oncology Programs
ROCKVILLE, MD, UNITED STATES, August 22, 2018 /EINPresswire.com/ — AGT announces the receipt of three foundational patents. Two new patents focus on the immuno-oncology program and add to AGT’s broad protection for its unique process of activating gamma delta T cells to attack solid tumors (“Methods and Composition for the Activation of Gamma Delta T… [Read More]
American Gene Technologies Congratulates Robert Redfield, M.D., on His Appointment as Director of the Centers for Disease Control and Prevention
ROCKVILLE, Md., March 28, 2018 (GLOBE NEWSWIRE) — American Gene Technologies International Inc. (AGT), a leading gene and cell therapy company, today congratulates Robert R. Redfield, M.D., on his appointment as the Director of the Centers for Disease Control and Prevention (CDC). Dr. Redfield has served as an advisor to AGT since 2011 and later became chair… [Read More]
BioWorld Reports American Gene Technologies’s Progress Toward an HIV cure
Newsletter Vol. 29, No. 18, Pg. 2 January 26, 2018 On January 26, 2018, BioWorld, The Daily Biopharmaceutical Newscource, published this story: American Gene Technologies International Inc. (AGT), of Rockville, Md., disclosed completion of the pilot runs of its HIV cure automated cell processing protocol. That completes a key milestone of the firm’s planned… [Read More]
American Gene Technologies Announces Progress toward Phase I Clinical Trial of AGT103-T for HIV cure
Completes process development for the AGT103-T automated cell manufacturing protocol ROCKVILLE, MD, January 25, 2018 — American Gene Technologies International Inc. (AGT), a leading gene and cell therapy company, today announced completion of the pilot runs of its HIV cure automated cell processing protocol. This completes a key milestone of AGT’s planned Phase I clinical trial… [Read More]
